1naresh

Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1nareshArray
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)

Demography and mean SII in the study population and healthy controls^{^a}
Patients with MS, Baseline Patients with MS, 9-Year Follow-Up Patients with MS, 18-Year Follow-Up Healthy Controls
Female/male (No.) 18:5 18:5 18:5 18:5
Age (yr) 39 ± 8.1 48 ± 8.1 57 ± 8.0 57 ± 7.2
Disease duration (yr) 10 ± 7 19 ± 7 27 ± 7 –
MS subtype: RR/SP/PP (No.) 18/5/0 13/10/0 3/20/0 –
Disease-modifying therapy (No.) (%) 13 (57%) 13 (57%) 5 (22%) –
Gadolinium administrations (median) (range) 1 (0–3) 3 (2–10) 6 (3–12) 0
Dentate nucleus SII, middle cerebellar peduncle as a reference 1.01 ± 0.02 1.03 ± 0.03 1.06 ± 0.05 1.01 ± 0.03^{^b}
Globus pallidus SII, thalamus as a reference 1.04 ± 0.05 1.06 ± 0.04 1.09 ± 0.06 1.10 ± 0.04^{^c}
Note:—PP indicates primary-progressive; RR, relapsing-remitting; SP, secondary-progressive.
↵a Values are reported as means, unless otherwise specified.
↵b The difference in SIIs between controls and patients with MS: unpaired t test (P < .001).
↵c The difference in SIIs between controls and patients with MS: unpaired t test (P =.19).